KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Cancer Commun (Lond) · 2026 · PMID 42282892

Panel A提取失败待 EXE 对齐验证

progression-free survival

Fig. 2. Kaplan–Meier survival curve and subgroup analysis of BICR-assessed progression-free survival, showing the progression-free survival benefits with serplulimab plus chemotherapy compared to chemotherapy alone in the intent-to-treat population and across subgroups. (A) In the ITT population. The median PFS was 12.0 (95% CI 8.7 to 13.9) months in group A, 11.0 (95% CI 8.4 to 12.7) months in group B, and 5.7 (95% CI 4.9 to 6.9) in group C. Serplulimab plus chemotherapy significantly improved PFS compared with chemotherapy alone with an HR of 0.54 (95% CI 0.43 to 0.68; P < 0.001). The addition of HLX04 did not translate to an improvement in PFS compared with serplulimab plus chemotherapy (HR = 1.02, 95% CI 0.80 to 1.28; P = 0.896). (B) Exploratory subgroup analysis of PFS in group B vs. group C, suggesting a PFS benefit with serplulimab plus chemotherapy over chemotherapy alone across the various patient subgroups. (C) Exploratory subgroup analysis of PFS in group A vs. group B, implying a lack of PFS benefit with HLX04 and serplulimab plus chemotherapy over serplulimab plus chemotherapy across the various patient subgroups. Group A, serplulimab plus HLX04 and chemotherapy; Group B, serplulimab plus HLX04 placebo and chemotherapy; Group C, serplulimab placebo plus HLX04 placebo and chemotherapy. Abbreviations: BICR, blinded independent central review; CI, confidence interval; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; NE, not evaluable; NR, not reached; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; TPS, tumor proportion score.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.16
质量通过否
预期曲线3
实际曲线0
X 范围-
Y 范围-
No curves extracted

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0failed待验证02026-07-23T16:47:12+00:00